At a glance
- Originator LEO Pharma
- Class Anti-inflammatories; Antipsoriatics; Benzoic acids
- Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dermatitis
Most Recent Events
- 25 Jul 2001 Discontinued-II for Dermatitis in European Union (Topical)
- 23 Nov 1998 No-Development-Reported for Dermatitis in European Union (Topical)
- 05 Jun 1996 New profile